SHANGHAI, China — Drugmakers competing in China’s rapidly expanding weight-loss market are promoting obesity awareness through metro stations, gyms, social media and sporting events, even as regulations prohibit direct-to-consumer advertising of prescription medicines. The campaigns by companies including Novo Nordisk, Eli Lilly, Pfizer and Innovent Biologics are drawing attention from experts who say some messaging could come close to crossing the line into drug advertising.